Literature DB >> 17277952

Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.

Yukihiko Kawasaki1, Sigeo Suzuki, Ayumi Matsumoto, Kei Takano, Kazuhide Suyama, Koichi Hashimoto, Junzo Suzuki, Hitoshi Suzuki, Mitsuaki Hosoya.   

Abstract

Recently, there have been reports on the efficacy of low-density lipoprotein (LDL) apheresis (LDL-A) for focal and segmental glomerulosclerosis (FSGS) in pediatric patients. However, there have been few reports on the long-term efficacy of LDL-A for FSGS in such patients. We report here a case of long-term efficacy of LDL-A for FSGS. The patient was a 13-year-old boy with FSGS who presented with steroid-resistant and cyclosporine-resistant nephrotic syndrome and hyperlipidemia. LDL-A was performed 24 times on one year. Following LDL-A, serum concentrations of LDL, very low-density lipoprotein (VLDL), apoprotein B, and vascular endothelial growth factor significantly decreased, and urinary excretion of protein also decreased. In addition, 3 years after LDL-A, the pathology findings on a second renal biopsy had improved. The patient has been in remission from FSGS for 12 years since LDL-A. These findings suggest that LDL-A may be useful in maintaining long-term remission from pediatric FSGS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277952     DOI: 10.1007/s00467-006-0426-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group.

Authors:  B R Gordon; S F Kelsey; D W Bilheimer; D C Brown; P C Dau; A M Gotto; D R Illingworth; P H Jones; S F Leitman; J S Prihoda
Journal:  Am J Cardiol       Date:  1992-10-15       Impact factor: 2.778

Review 2.  Primary focal segmental glomerulosclerosis.

Authors:  S M Korbet
Journal:  J Am Soc Nephrol       Date:  1998-07       Impact factor: 10.121

3.  Urinary podocytes in primary focal segmental glomerulosclerosis.

Authors:  M Hara; T Yanagihara; I Kihara
Journal:  Nephron       Date:  2001-11       Impact factor: 2.847

4.  Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy.

Authors:  Tsukasa Nakamura; Yasuhiro Kawagoe; Hiroshi Ogawa; Yoshihiko Ueda; Masanori Hara; Noriaki Shimada; Isao Ebihara; Hikaru Koide
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

5.  A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.

Authors:  Motoshi Hattori; Hiroko Chikamoto; Yuko Akioka; Hyogo Nakakura; Daisuke Ogino; Akira Matsunaga; Akira Fukazawa; Sanpei Miyakawa; Miyuki Khono; Hiroshi Kawaguchi; Katsumi Ito
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

Review 6.  Primary focal segmental glomerulosclerosis: clinical course and response to therapy.

Authors:  S M Korbet; M M Schwartz; E J Lewis
Journal:  Am J Kidney Dis       Date:  1994-06       Impact factor: 8.860

7.  The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.

Authors:  B L Kasiske; J A Velosa; C E Halstenson; P La Belle; A Langendörfer; W F Keane
Journal:  Am J Kidney Dis       Date:  1990-01       Impact factor: 8.860

8.  The long-term prognosis of patients with focal segmental glomerulosclerosis.

Authors:  J S Cameron; D R Turner; C S Ogg; C Chantler; D G Williams
Journal:  Clin Nephrol       Date:  1978-12       Impact factor: 0.975

9.  Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.

Authors:  M Hattori; K Ito; H Kawaguchi; T Tanaka; R Kubota; M Khono
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

Review 10.  Focal and segmental glomerulosclerosis: analogies to atherosclerosis.

Authors:  J R Diamond; M J Karnovsky
Journal:  Kidney Int       Date:  1988-05       Impact factor: 10.612

View more
  5 in total

Review 1.  An update on LDL apheresis for nephrotic syndrome.

Authors:  Rupesh Raina; Vinod Krishnappa
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

2.  Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.

Authors:  Gianpaolo Russi; Luciana Furci; Marco Leonelli; Riccardo Magistroni; Nicola Romano; Paolo Rivasi; Alberto Albertazzi
Journal:  J Med Case Rep       Date:  2009-12-02

3.  Effect of human very low-density lipoproteins on cardiotrophin-like cytokine factor 1 (CLCF1) activity.

Authors:  Sarah Pasquin; Salma Chehboun; Agnieszka Dejda; Yasmine Meliani; Virginia Savin; Gregory J Warner; Roger Bosse; Aurélie Tormo; Gaétan Mayer; Mukut Sharma; Przemyslaw Sapieha; Catherine Martel; Jean-François Gauchat
Journal:  Sci Rep       Date:  2018-03-05       Impact factor: 4.379

4.  Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study.

Authors:  Rupesh Raina; Vinod Krishnappa; Cheryl Sanchez-Kazi; Alejandro Quiroga; Katherine E Twombley; Robert Mathias; Megan Lo; Ronith Chakraborty; Shefali Mahesh; Julia Steinke; Timothy Bunchman; Joshua Zaritsky
Journal:  Front Pediatr       Date:  2019-12-03       Impact factor: 3.418

5.  A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Tsukasa Takemura; Yukio Yuzawa; Satoru Ogahara; Satoshi Sugiyama; Yasuhiko Iino; Soichi Sakai; Yousuke Ogura; Susumu Yukawa; Yoshiki Nishizawa; Noriaki Yorioka; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Nephron Extra       Date:  2015-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.